Form 4: Director Winston Kung Sells Corbus Pharmaceuticals Shares

Corbus Pharmaceuticals Director Winston Kung sold 2,026 shares of common stock via a pre-arranged Rule 10b5-1 trading plan.

Summary

• Director Winston Kung sold 2,026 shares of Corbus Pharmaceuticals common stock.
• The shares were sold at a weighted average price of $7.9137 per share.
• The transaction was executed on June 10, 2026, under a Rule 10b5-1 trading plan adopted on March 11, 2026.
• Following the sale, the director retains beneficial ownership of 12,140 shares, which includes 3,800 unvested restricted stock units (RSUs).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed through a pre-planned, automated trading program rather than an opportunistic market move.

Positives

• The sale was conducted under a pre-established Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell shares without triggering concerns regarding non-public information.

Negatives

• The transaction represents a reduction in the director's direct equity stake in the company.

Risks

• Insider selling can sometimes be perceived negatively by the market as a signal of management's view on the company's valuation or future prospects.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a routine corporate governance practice in the biotechnology sector, intended to provide liquidity for executives and directors while maintaining compliance with securities laws.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders in the U.S. pharmaceutical sector to manage personal equity holdings.
• The scale of the sale is relatively minor compared to the total outstanding shares of Corbus Pharmaceuticals.

Stakeholder Impact

• Minimal impact expected on shareholders as the transaction was pre-planned and represents a small portion of the director's holdings.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Corbus Pharmaceuticals, CRBP, Insider Trading, Form 4, Winston Kung, Equity Sale